Advertisement
MEDP or MTD or TMO
Which Stock Would AI Choose? Medpace Holdings (MEDP) vs. Mettler-Toledo International (MTD) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- Medpace Holdings (MEDP) is a fast-growing, mid-cap contract research organization (CRO) posting roughly 26% revenue growth, but rising project cancellations and a book-to-bill ratio below 1.0 have tempered sentiment.
- Mettler-Toledo International (MTD) delivers steady single-digit growth and strong capital returns, yet faces tariff, China-demand, and valuation-sensitivity concerns.
- Thermo Fisher Scientific (TMO) is the largest and most diversified of the three, holding a "Strong Buy" consensus and recently breaking out to multi-year highs on broad end-market recovery.
- All three trade at similar forward price-to-earnings multiples, but their scale, growth drivers, and risk profiles differ materially.
- Relative performance has diverged: TMO shows the strongest recent momentum, MTD has lagged year-to-date, and MEDP has been volatile around its cancellation narrative.
Introduction
This stock comparison examines three companies that sit at different points along the life sciences and healthcare-services value chain: MEDP, a clinical research specialist; MTD, a precision-instruments manufacturer; and TMO, a diversified life sciences and diagnostics leader. Growth-oriented investors may weigh MEDP's faster expansion, while quality-focused investors may prefer MTD's or TMO's scale, margins, and durability. Comparing relative performance and market positioning across these names helps traders assess where momentum, valuation, and risk currently intersect in the broader healthcare tools and services sector.
MEDP Overview and Recent Performance
Medpace Holdings (MEDP) is a Cincinnati-based contract research organization (CRO) that manages clinical trials for pharmaceutical, biotechnology, and medical-device companies, from Phase I through Phase IV. In recent market activity, MEDP has been driven by a powerful growth narrative: revenue rose about 26% year over year in its most recent reported quarter, and the shares have rallied substantially from their 52-week low. Analysts have lifted price targets, with firms such as Mizuho and RBC Capital maintaining Outperform ratings.
However, sentiment has been complicated by rising project cancellations, concentrated in oncology and cardiology studies, and a net book-to-bill ratio below 1.0, which measures whether new bookings are keeping pace with completed work. Management has characterized the cancellations as project-specific rather than funding-driven and expects gross bookings to accelerate in the second half of the year. The result is a stock with strong underlying demand but near-term visibility concerns that have kept the consensus rating at "Hold."
MTD Overview and Recent Performance
Mettler-Toledo International (MTD) is a global manufacturer of precision instruments, including laboratory balances, pipettes, pH meters, and product-inspection systems used across laboratory, industrial, and food-retail settings. The company has reported consistent single-digit revenue growth and beat adjusted earnings-per-share (EPS) estimates in recent quarters, while raising its full-year outlook and announcing a share-repurchase plan of roughly $875 million.
Sentiment around MTD reflects a balance of positives and headwinds. Service revenue, pricing power, and an improving China and emerging-markets outlook support the story, while tariff friction, soft demand in some Western biopharma and academic segments, and a premium valuation weigh on the shares. The stock has lagged the broader market on a year-to-date basis despite favorable long-term fundamentals, leaving analysts divided between Buy and Hold ratings at recent price levels.
TMO Overview and Recent Performance
Thermo Fisher Scientific (TMO) is the world's largest life sciences tools and services company, spanning analytical instruments, reagents, diagnostics, and biopharma services through brands such as Thermo Scientific, Fisher Scientific, Patheon, and PPD. With annual revenue above $45 billion, it serves pharmaceutical, biotech, academic, and government customers globally. Recent quarters have shown broad-based end-market improvement, with pharma and biotech demand leading growth and management raising full-year organic revenue guidance.
Recent market activity has been notably strong for TMO: the shares have posted a sizable 90-day gain and broken out to new highs, supported by a string of higher price targets and a "Strong Buy" consensus rating. Strategic moves, including the Clario and Solventum acquisitions and a planned microbiology divestiture, are reshaping the portfolio toward higher-value areas. The primary debate now centers on whether the current valuation already reflects the improving demand backdrop.
Trending AI Robots
For traders who prefer a data-driven, automated approach to comparing opportunities like these, Tickeron's Trending AI Robots page offers a curated view of the platform's best-performing AI trading bots. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only those most suitable for current market conditions earn a place in the Trending AI Robots section. These bots vary widely in trading style, strategy, timeframe, performance, and the set of tickers they trade, giving users a range of approaches to explore. Reviewing the featured bots can help investors identify systematic strategies that align with their own risk tolerance and market outlook.
Head-to-Head Comparison
The three names differ most sharply in business model and scale. MEDP is a pure-play CRO whose growth is tied to clinical-trial outsourcing and therapeutic mix shifts, making it more cyclical and sensitive to booking and cancellation trends. MTD operates as a diversified instrument maker with high gross margins and recurring service revenue, giving it steadier, lower-growth economics exposed to industrial and trade cycles. TMO combines both worlds at far greater scale, blending instruments, consumables, diagnostics, and pharma services to smooth out end-market volatility.
On relative performance, TMO has shown the strongest recent momentum, while MTD has underperformed year-to-date and MEDP has been choppy around its cancellation narrative. Valuation is more aligned than the profiles suggest, with all three trading at broadly comparable forward earnings multiples. The key trade-off is therefore one of growth versus stability: MEDP offers the highest revenue growth but the least earnings visibility, MTD offers quality and capital returns with macro sensitivity, and TMO offers scale and diversification with questions about how much of the recovery is already priced in.
Tickeron AI Verdict
Based on observable trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would most likely favor TMO in the current environment. The stock combines the strongest recent price momentum with the most supportive analyst backdrop and a diversified revenue base that reduces single-end-market risk. MEDP's faster growth is offset by booking and cancellation uncertainty, while MTD's steady economics are counterbalanced by tariff and China-related sensitivity. Using probabilistic language rather than definitive claims, TMO currently presents the most balanced risk-reward profile among the three, though its extended run leaves less margin for error if demand softens.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
MEDP in upward trend: price rose above 50-day moving average on October 05, 2026
MEDP moved above its 50-day moving average on October 05, 2026 date and that indicates a change from a downward trend to an upward trend. In 37 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on MEDP as a result. In 73 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for MEDP just turned positive on October 15, 2026. Looking at past instances where MEDP's MACD turned positive, the stock continued to rise in 40 of 52 cases over the following month. The odds of a continued upward trend are 77%.
Following a +6.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where MEDP advanced for three days, in 238 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 199 of 255 cases where MEDP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEDP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
MEDP broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 18 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. MEDP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (43.051) is normal, around the industry mean (66.137). P/E Ratio (38.570) is within average values for comparable stocks, (2.464). Projected Growth (PEG Ratio) (2.929) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.390) is also within normal values, averaging (9.775).
MTD in upward trend: 10-day moving average broke above 50-day moving average on September 24, 2026
The 10-day moving average for MTD crossed bullishly above the 50-day moving average on September 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for MTD just turned positive on September 17, 2026. Looking at past instances where MTD's MACD turned positive, the stock continued to rise in 31 of 48 cases over the following month. The odds of a continued upward trend are 65%.
Following a +3.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where MTD advanced for three days, in 193 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 130 of 224 cases where MTD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 58%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MTD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
MTD broke above its upper Bollinger Band on October 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 3 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 8 (best 1 - 100 worst), indicating outstanding price growth. MTD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 81 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MTD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock better than average.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: MTD's P/B Ratio (2609.909) is very high in comparison to the industry average of (66.137). P/E Ratio (37.551) is within average values for comparable stocks, (2.464). Projected Growth (PEG Ratio) (2.869) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.798) is also within normal values, averaging (9.775).
Momentum Indicator for TMO turns positive, indicating new upward trend
TMO saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In 56 of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at 64%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in 194 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 142 of 246 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 58%.
Bearish Trend Analysis
The 10-day RSI Indicator for TMO moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 19 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 51%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 66 cases where TMO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 58%.
The Moving Average Convergence Divergence Histogram (MACD) for TMO turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 23 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
TMO broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 16 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.729) is normal, around the industry mean (66.137). P/E Ratio (36.207) is within average values for comparable stocks, (2.464). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 77 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock better than average.
MEDP | MTD | TMO | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 40 | 39 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 99 Overvalued | 65 Fair valued | |
PROFIT vs RISK RATING 1..100 | 18 | 81 | 77 | |
SMR RATING 1..100 | 11 | 3 | 60 | |
PRICE GROWTH RATING 1..100 | 39 | 8 | 16 | |
P/E GROWTH RATING 1..100 | 54 | 30 | 27 | |
SEASONALITY SCORE 1..100 | 75 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (65) in the Medical Specialties industry is in the same range as MEDP (83) in the Miscellaneous Commercial Services industry, and is somewhat better than the same rating for MTD (99) in the Medical Specialties industry. This means that TMO's stock grew similarly to MEDP’s and somewhat faster than MTD’s over the last 12 months.
MEDP's Profit vs Risk Rating (18) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for TMO (77) in the Medical Specialties industry, and is somewhat better than the same rating for MTD (81) in the Medical Specialties industry. This means that MEDP's stock grew somewhat faster than TMO’s and somewhat faster than MTD’s over the last 12 months.
MTD's SMR Rating (3) in the Medical Specialties industry is in the same range as MEDP (11) in the Miscellaneous Commercial Services industry, and is somewhat better than the same rating for TMO (60) in the Medical Specialties industry. This means that MTD's stock grew similarly to MEDP’s and somewhat faster than TMO’s over the last 12 months.
MTD's Price Growth Rating (8) in the Medical Specialties industry is in the same range as TMO (16) in the Medical Specialties industry, and is in the same range as MEDP (39) in the Miscellaneous Commercial Services industry. This means that MTD's stock grew similarly to TMO’s and similarly to MEDP’s over the last 12 months.
TMO's P/E Growth Rating (27) in the Medical Specialties industry is in the same range as MTD (30) in the Medical Specialties industry, and is in the same range as MEDP (54) in the Miscellaneous Commercial Services industry. This means that TMO's stock grew similarly to MTD’s and similarly to MEDP’s over the last 12 months.
| MEDP | MTD | TMO | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 86% | 2 days ago 74% | 2 days ago 51% |
| Stochastic ODDS (%) | 2 days ago 70% | 2 days ago 61% | 2 days ago 58% |
| Momentum ODDS (%) | 2 days ago 74% | N/A | 2 days ago 64% |
| MACD ODDS (%) | 2 days ago 77% | 6 days ago 65% | 2 days ago 53% |
| TrendWeek ODDS (%) | 2 days ago 76% | 2 days ago 61% | 2 days ago 60% |
| TrendMonth ODDS (%) | 2 days ago 78% | 2 days ago 60% | 2 days ago 62% |
| Advances ODDS (%) | 4 days ago 75% | 3 days ago 61% | 4 days ago 63% |
| Declines ODDS (%) | 27 days ago 63% | 24 days ago 66% | 2 days ago 62% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 71% | 2 days ago 57% |
| Aroon ODDS (%) | 2 days ago 78% | 2 days ago 58% | 2 days ago 58% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MEDP’s FA Score shows that 2 FA rating(s) are green while MTD’s FA Score has 3 green FA rating(s), and TMO’s FA Score reflects 2 green FA rating(s).
- MEDP’s FA Score: 2 green, 3 red.
- MTD’s FA Score: 3 green, 2 red.
- TMO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MEDP’s TA Score shows that 5 TA indicator(s) are bullish while MTD’s TA Score has 4 bullish TA indicator(s), and TMO’s TA Score reflects 3 bullish TA indicator(s).
- MEDP’s TA Score: 5 bullish, 4 bearish.
- MTD’s TA Score: 4 bullish, 4 bearish.
- TMO’s TA Score: 3 bullish, 5 bearish.
Price Growth
MEDP (@Medical Specialties) experienced а +8.20% price change this week, while MTD (@Medical Specialties) price change was +2.96% , and TMO (@Medical Specialties) price fluctuated -2.34% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.55%. For the same industry, the average monthly price growth was -5.91%, and the average quarterly price growth was +42.02%.
Reported Earning Dates
MEDP is expected to report earnings on Feb 15, 2027.
MTD is expected to report earnings on Nov 05, 2026.
TMO is expected to report earnings on Feb 04, 2027.
Industries' Descriptions
@Medical Specialties (+1.55% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement